PriceTargets.com logo

Balchem - BCPC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $140.00
  • Forecasted Upside: 14.50%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$122.27 As of 03/24/2023 01:01 PM ET
▲ +0.93 (0.77%)

This chart shows the closing price for BCPC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Balchem Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BCPC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BCPC

Analyst Price Target is $140.00
▲ +14.50% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Balchem in the last 3 months. The average price target is $140.00, with a high forecast of $140.00 and a low forecast of $140.00. The average price target represents a 14.50% upside from the last price of $122.27.

This chart shows the closing price for BCPC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Balchem. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/29/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/28/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/27/2023HC WainwrightLower Target$152.00 ➝ $140.00Low
11/7/2022HC WainwrightLower TargetBuy$164.00 ➝ $152.00Low
8/22/2022HC WainwrightBoost TargetBuy$152.00 ➝ $164.00Low
5/2/2022HC WainwrightLower TargetBuy$155.00 ➝ $152.00Medium
3/8/2022HC WainwrightLower TargetBuy$170.00 ➝ $155.00Medium
2/22/2022SidotiUpgradeNeutral ➝ Buy$175.00Medium
1/10/2022HC WainwrightBoost TargetBuy$160.00 ➝ $170.00High
11/29/2021SidotiDowngradeBuy ➝ Neutral$175.00Medium
8/2/2021StephensDowngradeOverweight ➝ Equal Weight$140.00 ➝ $145.00High
8/2/2021HC WainwrightBoost TargetBuy$145.00 ➝ $160.00High
2/22/2021HC WainwrightBoost TargetBuy$126.00 ➝ $145.00High
2/22/2021StephensUpgradeEqual Weight ➝ Overweight$100.00 ➝ $140.00High
8/4/2020HC WainwrightBoost TargetBuy$104.00 ➝ $126.00Medium
7/9/2020StephensInitiated CoverageEqual Weight$100.00Medium
5/4/2020HC WainwrightLower TargetBuy$116.00 ➝ $104.00High
2/24/2020HC WainwrightLower TargetBuy$122.00 ➝ $116.00High
1/31/2020HC WainwrightReiterated RatingBuy$110.00 ➝ $122.00High
11/6/2019HC WainwrightReiterated RatingBuy ➝ Positive$95.00 ➝ $110.00High
8/5/2019HC WainwrightReiterated RatingBuy$110.00 ➝ $95.00High
5/6/2019HC WainwrightReiterated RatingBuy$110.00Low
5/6/2019Pivotal ResearchDowngradeBuy ➝ Hold$100.00High
2/5/2019HC WainwrightSet TargetBuy$101.00High
12/10/2018HC WainwrightSet TargetBuy$101.00High
11/6/2018Pivotal ResearchUpgradeHold ➝ Buy$95.00 ➝ $100.00Low
10/16/2018SidotiUpgradeNeutral ➝ Buy$127.00High
10/15/2018HC WainwrightSet TargetBuy$140.00Low
9/25/2018HC WainwrightInitiated CoverageBuy ➝ BuyLow
8/3/2018Pivotal ResearchBoost TargetHold$85.00 ➝ $95.00High
5/7/2018Vertical ResearchDowngradeBuy ➝ HoldMedium
5/7/2018Pivotal ResearchUpgradeSell ➝ Hold$85.00Medium
(Data available from 3/24/2018 forward)

News Sentiment Rating

1.14 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/26/2022
  • 4 very positive mentions
  • 4 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
9/25/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/25/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/24/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/24/2022
  • 8 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/23/2023
  • 11 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/22/2023
  • 12 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2023

Current Sentiment

  • 12 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Balchem logo
Balchem Corp. provides marketing of specialty performance ingredients and products. It operates through the following segments: Human Nutrition and Health, Animal Nutrition and Health, Specialty Products and Industrial Products. The Human Nutrition and Health segment supplies ingredients in the food and beverage industry, providing customized solutions in powder, solid and liquid flavor delivery systems, spray dried emulsified powder systems, and cereal systems. The Animal Nutrition and Health segment comprises nutritional products derived from microencapsulation and chelation technologies in addition to basic choline chloride. The Specialty Products segment offers Ethylene oxide for the health care industry. The Industrial Products segment refers to certain derivatives of choline chloride which manufactured and sold into industrial applications as a component for hydraulic fracturing of shale natural gas wells. The company was founded in January 1967 and is headquartered in Montvale, NJ.
Read More

Today's Range

Now: $122.27
Low: $118.60
High: $122.63

50 Day Range

MA: $131.14
Low: $121.34
High: $142.06

52 Week Range

Now: $122.27
Low: $110.15
High: $143.88

Volume

25,896 shs

Average Volume

105,327 shs

Market Capitalization

$3.93 billion

P/E Ratio

37.62

Dividend Yield

0.56%

Beta

0.69

Frequently Asked Questions

What sell-side analysts currently cover shares of Balchem?

The following Wall Street research analysts have issued stock ratings on Balchem in the last year: HC Wainwright, and StockNews.com.
View the latest analyst ratings for BCPC.

What is the current price target for Balchem?

1 Wall Street analysts have set twelve-month price targets for Balchem in the last year. Their average twelve-month price target is $140.00, suggesting a possible upside of 15.4%. HC Wainwright has the highest price target set, predicting BCPC will reach $140.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $140.00 for Balchem in the next year.
View the latest price targets for BCPC.

What is the current consensus analyst rating for Balchem?

Balchem currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BCPC will outperform the market and that investors should add to their positions of Balchem.
View the latest ratings for BCPC.

What other companies compete with Balchem?

Other companies that are similar to Balchem include Ashland, Innospec, Livent, Chemours and Huntsman. Learn More about companies similar to Balchem.

How do I contact Balchem's investor relations team?

Balchem's physical mailing address is 52 Sunrise Park Road, NEW HAMPTON NY, 10958. The basic materials company's listed phone number is (845) 326-5600 and its investor relations email address is [email protected] The official website for Balchem is www.balchem.com. Learn More about contacing Balchem investor relations.